RET融合阳性肺癌一线化疗联合免疫治疗与单纯化疗的结局:LIBRETTO-431次要分析
LIBRETTO-431是一项全球多中心3期注册研究,RET融合阳性肺癌患者随机接受selpercatinib或铂类双药化疗(培美曲塞联合卡铂或顺铂),可联合或不联合帕博利珠单抗。基于该研究总体结果,选择性RET抑制剂仍是RET融合阳性NSCLC首选一线治疗。
要点
- 化疗联合免疫治疗与单纯化疗的PFS(p=0.8)和OS(p>0.9)均无显著差异。
- 对这类致癌基因驱动肿瘤,单纯化疗是合理策略。
- 选择性RET抑制剂仍是RET融合阳性NSCLC首选一线治疗。
核心结论
- 在RET融合阳性晚期肺癌中,一线化疗联合免疫治疗与单纯化疗的结局无显著差异,单纯化疗是合理策略。
- 基于LIBRETTO-431总体结果,选择性RET抑制剂仍是RET融合阳性NSCLC的首选一线治疗。
研究设计与样本
- LIBRETTO-431为注册性3期研究,RET融合阳性肺癌患者随机接受selpercatinib或铂类双药化疗(培美曲塞联合卡铂或顺铂),可联合或不联合帕博利珠单抗。
主要发现
- 两组吸烟史(p=0.10)、PD-L1状态(p=0.3)、基线脑转移(p=0.8)均无显著差异。
- 盲态独立中心评估的中位PFS在化疗联合免疫治疗组为11.2个月(95%CI:10.9-16.8),单纯化疗组未达到(95%CI:4.9-未达到),两组PFS无显著差异(p=0.8)。
- 两组中位OS均未达到,OS无显著差异(p>0.9)。
临床怎么用
- 对RET融合阳性晚期NSCLC,单纯化疗可作为合理的一线选择。
- 一线治疗仍应优先考虑选择性RET抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Single-agent checkpoint inhibitor therapy achieves suboptimal outcomes in patients with advanced RET fusion-positive lung cancer. Prospective data on the role of adding checkpoint inhibitor therapy to platinum doublet chemotherapy have not previously been available. METHODS: In the registrational, phase 3 LIBRETTO-431 study, patients with RET fusion-positive lung cancer were randomized to receive selpercatinib or platinum-doublet chemotherapy (pemetrexed and carboplatin or cisplatin) with or without pembrolizumab. An analysis of outcomes, including progression-free survival (PFS) and overall survival (OS) in patients treated with chemoimmunotherapy and chemotherapy alone, was performed. RESULTS: Eighty-three patients received chemoimmunotherapy, and 19 patients received chemotherapy alone. No significant differences in smoking history (p = 0.10), programmed death-ligand 1 status (p = 0.3), or baseline brain metastases (p = 0.8) were identified between the two groups. The median PFS by blinded independent central review was 11.2 months (95% confidence interval: 10.9-16.8) in chemoimmunotherapy-treated patients and not reached (95% confidence interval: 4.9-not reached) in chemotherapy-treated patients. PFS by blinded independent central review was not significantly different (p = 0.8) between chemoimmunotherapy- and chemotherapy-treated patients. The median OS was not reached for either group. OS did not significantly differ (p > 0.9) between chemoimmunotherapy- and chemotherapy-treated patients. CONCLUSIONS: In patients with advanced RET fusion-positive lung cancer treated in this global, multicenter trial, outcomes with first-line chemoimmunotherapy and chemotherapy were not significantly different in this secondary analysis. Using chemotherapy alone is a reasonable strategy for these oncogene-driven tumors. Based on the overall findings from LIBRETTO-431, selective RET inhibitors remain the preferred first-line therapy for patients with RET fusion-positive non-small cell lung cancer.
引用
- Cui C, Lin S, Waliany S, et al. First-Line Chemoimmunotherapy and Chemotherapy Outcomes in Patients With RET Fusion-Positive Lung Cancer in LIBRETTO-431. J Thorac Oncol. 2026. PMID: 42431264. doi:10.1016/j.jtho.2026.104086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。